NCT01001442 - Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

July 31, 2014

Study Completion Date

March 31, 2016

Conditions

Multiple Myeloma

Interventions

DRUG

BT062

intravenous administration

Trial Locations (5)

The Mount Sinai School of Medicine, New York

Roswell Park Cancer Institute, Buffalo

Emory University Winship Cancer Institute, Atlanta

The University of Chicago, Chicago

Dana-Farber Cancer Institute, Boston